北京赛升药业股份有限公司 第五届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 北京赛升药业股份有限公司（以下简称"公司"）第五届董事会第十次会议 于2025年10月22日在公司会议室召开，本次会议于2025年10月17日以通讯的方式 向所有董事送达了会议通知。应参与会议董事8名，实际参会董事8人，会议由董 事长马骉主持，公司监事、高级管理人员列席了本次会议。本次会议的召开符合 《中华人民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定，会议决议合法、有效。 二、会议审议情况 经全体董事认真审议并表决，会议通过了以下议案： 1、审议通过《关于公司<2025年第三季度报告>的议案》 公司《2025 年第三季度报告》的编制程序符合法律、法规和中国证监会的 有关规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在任何虚 假记载、误导性陈述或者重大遗漏。具体内容详见中国证监会指定的创业板信息 披露网站巨潮资讯网（http://www.cninfo.com.cn）。 证券代码：300485 ...

Group 1 - The core viewpoint of the announcement indicates that the company's third-quarter revenue reached 112 million yuan, representing a year-on-year increase of 3.50% [1] - The net profit for the third quarter was 4.0733 million yuan, showing a significant decline of 41.41% compared to the previous year [1] - For the first three quarters, the total revenue amounted to 309 million yuan, which reflects a year-on-year decrease of 4.41% [1] - The net profit for the first three quarters was 51.8596 million yuan, marking a substantial increase of 152.81% year-on-year [1]

北京赛升药业股份有限公司 2025 年第三季度报告 证券代码：300485 证券简称：赛升药业 公告编号：2025-039 北京赛升药业股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度财务会计报告是否经过审计 □是 ☑否 1 北京赛升药业股份有限公司 2025 年第三季度报告 一、主要财务数据 公司是否需追溯调整或重述以前年度会计数据 □是 ☑否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末比上 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 增减 | 年同期增减 | | | 营业收入（元） | 111,825,972.85 | 3.50% | 308,627,146 ...

中证2000指数ETF（159536）业绩比较基准为中证2000指数收益率，管理人为汇添富基金管理股份有限 公司，基金经理为孙浩，成立（2023-09-13）以来回报为35.34%，近一个月回报为-2.79%。 来源：新浪基金∞工作室 10月17日，中证2000指数ETF（159536）开盘涨0.22%，报1.354元。中证2000指数ETF（159536）重仓 股方面，三德科技开盘跌0.88%，汉威科技跌0.11%，赛升药业跌0.88%，中光防雷涨0.00%，飞龙股份 跌0.56%，普邦股份涨0.00%，星帅尔跌0.55%，新联电子跌0.82%，新开普涨0.58%，潮宏基涨0.59%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 ...

Core Insights - The biopharmaceutical sector experienced a slight increase of 0.13% on October 16, with Sanofi leading the gains [1] - The Shanghai Composite Index closed at 3916.23, up 0.1%, while the Shenzhen Component Index closed at 13086.41, down 0.25% [1] Biopharmaceutical Sector Performance - Sanofi (688336) saw a significant rise of 13.02%, closing at 59.90 with a trading volume of 177,400 shares and a transaction value of 1.063 billion [1] - Other notable gainers included: - Nossland (920047) up 4.09% to 25.46 with a transaction value of 125 million [1] - Rongchang Bio (688331) up 3.28% to 99.20 with a transaction value of 684 million [1] - Conversely, several companies experienced declines, including: - Anke Bio (300009) down 2.48% to 10.23 with a transaction value of 315 million [2] - Kain Technology (688687) down 1.92% to 28.62 with a transaction value of 169 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 2.7582 million from institutional investors, while retail investors experienced a net outflow of 140 million [2] - Notable capital inflows included: - Junshi Biosciences (688180) with a net inflow of 71.7936 million from institutional investors [3] - Sanofi (688336) with a net inflow of 67.508 million from institutional investors [3] - Conversely, significant outflows were observed in: - Sanofi (688336) with a retail net outflow of 540,300 [3] - Rongchang Bio (688331) with a retail net outflow of 4.41034 million [3]

Core Insights - The biopharmaceutical sector experienced a rise of 1.78% on October 15, with Sai Sheng Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Company Performance - Sai Sheng Pharmaceutical (300485) closed at 12.28, with a gain of 9.16% and a trading volume of 369,300 shares [1] - Kanghua Biological (300841) closed at 77.71, up 6.02%, with a trading volume of 49,400 shares [1] - Kangchen Pharmaceutical (603590) closed at 49.11, increasing by 5.84%, with a trading volume of 40,700 shares [1] - San Sheng Guo Jian (688336) closed at 53.00, up 5.68%, with a trading volume of 56,800 shares [1] - Bai Pu Sai Si (301080) closed at 57.73, gaining 5.23%, with a trading volume of 28,000 shares [1] - Rongchang Biological (688331) closed at 96.05, up 5.20%, with a trading volume of 72,700 shares [1] - Shenzhou Cell (688520) closed at 55.03, increasing by 4.90%, with a trading volume of 42,700 shares [1] - Kang Le Wei Shi (920575) closed at 12.94, up 4.61%, with a trading volume of 53,900 shares [1] - Tonghua Dongbao (600867) closed at 8.96, gaining 4.55%, with a trading volume of 543,800 shares [1] - Olin Biological (61688919) closed at 24.96, up 4.22%, with a trading volume of 65,800 shares [1] Market Capital Flow - The biopharmaceutical sector saw a net inflow of 331 million yuan from institutional investors, while retail investors experienced a net outflow of 234 million yuan [2] - The main funds showed a net inflow in several companies, including Changchun High-tech (000661) with 66.94 million yuan and Tonghua Dongbao (600867) with 62.56 million yuan [3] - Retail investors showed significant outflows in companies like Sai Sheng Pharmaceutical (300485) with 50.24 million yuan and Rongchang Biological (688331) with 38.34 million yuan [3]

Market Overview - Major A-share indices experienced slight fluctuations in the morning and rose in the afternoon, with the Shanghai Composite Index increasing by 1.22% to close at 3912.21 points, the Shenzhen Component Index rising by 1.73%, and the ChiNext Index up by 2.36% [1][2]. Trading Volume - The total market turnover reached 2.09 trillion yuan, a decrease of 506.2 billion yuan compared to the previous trading day, with over 4300 stocks rising [1]. Sector Performance - The robotics sector surged following the release of a document by Shanghai supporting the research and mass production of humanoid robots, with Sanhua Intelligent Control hitting the daily limit [3]. - The automotive sector also performed well, with Zhongtong Bus and Haima Automobile both reaching the daily limit [3]. - The recombinant protein and CRO sectors were active, led by Sai Sheng Pharmaceutical and Boteng Co., Ltd. [3]. - The aviation and airport sectors saw gains, with Huaxia Airlines hitting the daily limit [3]. - Other sectors with notable increases included high-pressure fast charging, Kirin batteries, precious metals, automotive parts, and chemical pharmaceuticals [3]. Declining Sectors - The shipping and port sector declined, with Nanjing Port dropping over 7% [3]. - The small metals and rare earth permanent magnet sectors retreated, with Galaxy Magnetic Materials leading the decline [3]. - The photolithography machine sector weakened, with New Lai Material falling over 12% [3]. - Other sectors with significant declines included grain concepts, genetically modified organisms, cultivated diamonds, and electronic chemicals [3].

Market Performance - Major A-share indices experienced slight fluctuations in the morning and surged in the afternoon, with the Shanghai Composite Index rising by 1.22% to 3912 points, the Shenzhen Component Index increasing by 1.73%, and the ChiNext Index climbing by 2.36% [1] - The total market turnover was 2.09 trillion yuan, a decrease of 506.2 billion yuan compared to the previous trading day, with over 4300 stocks rising [1] Sector Performance - The robotics sector saw gains following the issuance of a document by Shanghai supporting the research and mass production of humanoid robots, with Sanhua Intelligent Control hitting the daily limit [1] - The automotive sector also performed well, with Zhongtong Bus and Haima Automobile both reaching the daily limit [1] - The recombinant protein and CRO sectors were active, led by Sai Sheng Pharmaceutical and Boteng Co., Ltd. [1] - The aviation and airport sectors rose, with Huaxia Airlines hitting the daily limit [1] - Other sectors with notable gains included high-pressure fast charging, Kirin batteries, precious metals, automotive parts, and chemical pharmaceuticals [1] Declining Sectors - The shipping and port sector declined, with Nanjing Port dropping over 7% [1] - The small metals and rare earth permanent magnet sectors retreated, with Galaxy Magnetic Materials leading the decline [1] - The photolithography machine sector weakened, with Xinlai Materials falling over 12% [1] - Other sectors with significant declines included grain concepts, genetically modified organisms, cultivated diamonds, and electronic chemicals [1] Recent Fund Inflows - Recent net inflows were observed in sectors such as precious metals, engineering machinery, and electrical power networks, with respective increases of 2.93%, 3.26%, and 3.18% [2] - Other sectors with notable increases included motorcycles and electronic components, with increases of 2.70% and 2.68% respectively [2]

E-commerce Sector - The e-commerce sector saw a strong performance with a near 3% increase in the index, driven by stocks like RuYuchen, YiWanYiChuang, and QingMuKeJi [2] - The "Double Eleven" shopping festival has officially started, with major platforms like Taobao and Tmall launching their promotions, following JD's early start [3] - Online retail sales in China from January to August increased by 9.6%, with significant growth in digital products such as smart wearables and computers, which grew by 25.2% and 23.7% respectively [4] Pharmaceutical Sector - The pharmaceutical and biotech sector experienced a collective surge, particularly in innovative drugs, with the index rising over 2% [7] - Companies like Asia Pacific Pharmaceutical and Guangsheng Tang saw significant stock price increases, with some stocks hitting the daily limit [7] - The IPO market for innovative drugs is heating up, with a focus on cutting-edge fields such as small molecule drugs and antibody-drug conjugates [9] Cross-border E-commerce - Cross-border e-commerce is rapidly expanding, with sales of Indonesian bird's nest and Kazakh safflower oil increasing by 160.1% and 143.2% respectively from January to August [6] - The growth in e-commerce promotions is expected to release potential consumer demand, benefiting shelf e-commerce [6] New Listings - XuanZhu Bio debuted on the Hong Kong Stock Exchange, initially surging over 167% before stabilizing at a still significant increase of over 130% [10][11] - XuanZhu Bio focuses on "digestion + oncology" and is also entering the NASH market, which currently lacks approved therapies in China, indicating a large unmet need [12] Market Trends - The overall A-share market showed slight fluctuations, with major indices experiencing mixed results, but the number of rising stocks outnumbered those that fell [5] - The innovative drug sector is expected to see a transformation driven by business development (BD) opportunities and new product launches, with a record 95 BD transactions in China's innovative drug sector since 2025 [12]

E-commerce Sector - The e-commerce sector is experiencing a strong rally, with the index rising nearly 3% as the "Double Eleven" shopping festival begins, leading to significant gains for stocks like Zhenai Meijia, which hit the daily limit shortly after market open [2][3] - Online retail sales in China from January to August increased by 9.6%, with notable growth in smart wearables, computers, and mobile phones, which saw increases of 25.2%, 23.7%, and 20.2% respectively [4] - Cross-border e-commerce is also thriving, with sales of Indonesian bird's nest, Kazakh safflower oil, and Uzbek candy growing by 160.1%, 143.2%, and 94.6% respectively [6] Pharmaceutical Sector - The pharmaceutical and biotech sector is witnessing a surge, particularly in innovative drugs, with the index rising over 2% and stocks like Yatai Pharmaceutical and Guangsheng Tang hitting the daily limit [7] - The Hong Kong Stock Exchange is seeing a wave of IPOs in the innovative drug sector, covering advanced fields such as small molecule drugs and antibody-drug conjugates [9] - Xuan Zhu Bio, focusing on "digestion + oncology," has seen its stock price soar over 167% on its debut, indicating strong market interest [10][11] Market Overview - The A-share market is showing slight fluctuations, with major indices mixed, but the number of rising stocks exceeds those that are falling [5] - The overall trend indicates a potential release of consumer demand due to e-commerce promotions, which may benefit shelf e-commerce and accelerate the online transformation of supermarkets and convenience stores [6]